Dragonfly Therapeutics Announces Collaboration with AbbVie for Autoimmune Diseases and Oncology

Date : 11/20/2019 @ 1:00PM
Source : PR Newswire (US)
Stock : AbbVie Inc (ABBV)
Quote : 87.263  0.543 (0.63%) @ 3:47PM

Dragonfly Therapeutics Announces Collaboration with AbbVie for Autoimmune Diseases and Oncology

AbbVie (NYSE:ABBV)
Historical Stock Chart

1 Month : From Nov 2019 to Dec 2019

Click Here for more AbbVie Charts.

Dragonfly will use its TriNKET™ platform to develop drug candidates directed to multiple targets for autoimmune disorders, and oncology.  AbbVie receives exclusive options to license a number of Dragonfly's natural killer (NK) cell engager immunotherapies.

WALTHAM, Mass., Nov. 20, 2019 /PRNewswire/ -- Dragonfly Therapeutics ("Dragonfly"), a biotechnology company developing novel immunotherapies that harness the innate immune system to treat disease, and AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced a multi-target research collaboration designed to advance a number of Dragonfly's novel NK cell engager-based immunotherapies for autoimmune and oncology indications.

Dragonfly Therapeutics, Inc.

The collaboration grants AbbVie the option to license exclusive worldwide intellectual property rights to develop and commercialize products directed to specific targets developed using Dragonfly's TriNKET™ technology platform. 

"AbbVie is committed to delivering improved treatment options to our patients by investing in groundbreaking technologies and platforms," said Tom Hudson, M.D. Senior Vice President, R&D and Chief Scientific Officer at AbbVie.  "The Dragonfly team has made impressive progress in developing their platform and demonstrating the potential of their technology to potentially treat a variety of diseases."

"AbbVie is a global leader in treating chronic immune-mediated diseases, and transforming standards of care for people living with cancer," said Bill Haney, co-founder and chief executive officer of Dragonfly. "We look forward to working with the AbbVie team to advancing new treatment options for patients."

AbbVie will pay Dragonfly an upfront payment, future success-based milestone payments and royalties.

About Dragonfly
Dragonfly Therapeutics is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing therapies that use its novel TriNKET™ technology to harness the body's innate immune system to bring breakthrough cancer treatments to patients. 

For more information visit: 
www.dragonflytx.com 
https://www.linkedin.com/company/dragonfly-therapeutics-inc.  
https://twitter.com/dragonflytx

DRAGONFLY MEDIA CONTACT:
Anne Deconinck | anne@dragonflytx.com

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/dragonfly-therapeutics-announces-collaboration-with-abbvie-for-autoimmune-diseases-and-oncology-300961954.html

SOURCE Dragonfly Therapeutics, Inc.

Copyright 2019 PR Newswire

Latest ABBV Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts


Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.


NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.